The intricacies of the False Claims Act (FCA) have long sparked debate within federal courts, especially concerning the critical element of causation. Recent developments highlight this ongoing controversy, particularly in relation to the Anti-Kickback Statute (AKS). Legal professionals are closely watching the proceedings in United States v. Regeneron Pharmaceuticals, Inc., a case that could serve as a landmark in this complex legal landscape.
In February, the US Court of Appeals for the First Circuit addressed the burdens of proof required by the government for the causation element under the FCA, ruling that a “but-for” standard must be met. This decision has exacerbated an existing circuit split. On one side, the Third Circuit maintains a more lenient criterion, demanding only a connection between the illicit kickback and the claim. Conversely, the Sixth and Eighth Circuits, along with now the First Circuit, uphold a more stringent but-for standard.
The debate centers around the Specifics of the 2010 amendment to the AKS, which states that claims “resulting from” a violation constitute false claims under the FCA. The interpretation of “resulting from” is pivotal, dictating whether a more relaxed or rigorous threshold applies for establishing causation. The AKS itself underpins much of this discussion, given its implications for federal healthcare programs.
The case against Regeneron challenges the company’s alleged actions to fund charities, supposedly to facilitate prescriptions for their drug, Eylea. The government argues this constitutes a violation of the AKS, hence defrauding federal programs like Medicare. As the lower courts continue to explore these issues, the First Circuit’s decision to adhere to a but-for causation aligns it with previous higher court rulings, challenging the government’s preference for a looser causal link.
The Supreme Court’s involvement could be decisive. While the lack of immediate certiorari means the matter remains unresolved at the highest federal level, it underscores a climate of legal uncertainty. As Attorney Stuart Silverman notes, the circuit discrepancies highlight an urgent need for the Supreme Court to deliver clarity on the matter.
This issue holds profound implications for the healthcare sector, given the potential for significant financial liabilities linked with FCA violations. Until the Supreme Court deems it necessary to definitively interpret the FCA’s causation requirement, stakeholders across the legal spectrum will have to maneuver through a landscape marked by inconsistency and regional variance.